Tumour initiation in mouse skin by 7,12-dimethylbenz[a]anthracene: irrelevance of systemic activation

Area of Science:

• Biochemistry
• Toxicology
• Carcinogenesis

Background:

• 7,12-dimethylbenz[a]anthracene (DMBA) is a potent carcinogen.
• Tumor initiation is a critical step in cancer development.
• Metabolic activation is essential for DMBA's carcinogenic activity.

Purpose of the Study:

• To investigate the inhibitory effect of 7,8-benzoflavone (BF) on DMBA-induced tumor initiation.
• To determine the relationship between BF administration timing and tumor initiation.
• To elucidate the role of epidermal enzymes in DMBA activation.

Main Methods:

• Administration of DMBA and BF via intragastric and topical routes.
• Assessment of tumor initiation following chemical exposure.
• Analysis of the time-dependent effects of BF on DMBA initiation.

Main Results:

• A single topical application of BF markedly reduced tumor initiation by DMBA through both administration routes.
• The inhibitory effect of BF was inversely proportional to the time interval between DMBA and BF administration.
• Data indicate that epidermal cytochrome P-448 dependent monooxygenases mediate the critical metabolic activation step of DMBA.

Conclusions:

• 7,8-benzoflavone acts as an effective inhibitor of DMBA-induced tumor initiation.
• The timing of BF administration is crucial for its anti-tumor initiation efficacy.
• Epidermal cytochrome P-448 dependent monooxygenases are key targets for modulating DMBA carcinogenicity.